Last reviewed · How we verify
PAL-40 Active
PAL-40 Active is a monoclonal antibody that targets the PD-1 receptor.
PAL-40 Active is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | PAL-40 Active |
|---|---|
| Sponsor | US Department of Veterans Affairs |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, PAL-40 Active prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Diarrhea
- Fatigue
Key clinical trials
- Homocysteine Study (HOST) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAL-40 Active CI brief — competitive landscape report
- PAL-40 Active updates RSS · CI watch RSS
- US Department of Veterans Affairs portfolio CI